tirzepatide metabolic syndrome is a next-generation dual agonist that targets both GLP-1 and GIP receptors to help regulate appetite, support balance, and drive meaningful weight loss. To match your unique physiology and treatment Shifting the Scales: Tirzepatide's Breakthrough

This means it activates two naturally occurring hormone pathways at once

Supply Shortages In late 2024 and early 2025, the UK had significant shortages of GLP-1 medicines, especially: Wegovy, because demand is very high Ozempic, which caused problems for some diabetes patients If you are considering starting treatment, discuss the available options with your doctor

Fatigue: Feeling tired or fatigued can occur, especially as your body begins to adjust to the weight loss medication

This discovery changed the landscape of weight loss medicine, and in November 2023, the UKs MHRA officially approved it for weight management

This Is Common Early On Feeling hungry during the first few weeks is very common, and expected

Whats not included: Lab work (if your provider decides blood work is necessary, you pay separately)